HELT and larynx cancer: TE671 rhabdomyosarcoma, T98G glioblastoma, MDA-MB-468 breast cancer, and NCI-H1299 larynx cancer cells showed the best response to MGN treatment [1], and thus, these cell lines were further used to explore a possible underlying MGN-mediated mechanism of anti-cancer action on the cellular level.